Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

FLJ11730 (N-Term) antibody

Reactivity: Human IHC, WB Host: Rabbit Polyclonal unconjugated
Catalog No. ABIN630964
  • Target
    FLJ11730
    Binding Specificity
    N-Term
    Reactivity
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Host
    • 2
    Rabbit
    Clonality
    • 2
    Polyclonal
    Conjugate
    • 2
    Un-conjugated
    Application
    • 2
    • 2
    • 1
    Immunohistochemistry (IHC), Western Blotting (WB)
    Specificity
    FLJ11730 antibody was raised against the N terminal Of Flj11730
    Purification
    Affinity purified
    Immunogen
    FLJ11730 antibody was raised using the N terminal Of Flj11730 corresponding to a region with amino acids HNKAAPPQIPDTRRELAELVKRKQELAETLANLERQIYAFEGSYLEDTQM
  • Application Notes
    WB: 0.5 µg/mL, IHC: 4-8 µg/mL
    Optimal conditions should be determined by the investigator.
    Comment

    FLJ11730 Blocking Peptide, catalog no. 33R-3801, is also available for use as a blocking control in assays to test for specificity of this FLJ11730 antibody

    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Lyophilized powder. Add distilled water for a 1 mg/mL concentration of FLJ11730 antibody in PBS
    Concentration
    Lot specific
    Buffer
    PBS
    Handling Advice
    Avoid repeated freeze/thaw cycles.
    Dilute only prior to immediate use.
    Storage
    4 °C/-20 °C
    Storage Comment
    Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
  • Target
    FLJ11730
    Background
    The screening of cDNA expression libraries from human tumors with serum antibody (SEREX) has proven to be a powerful method for identifying the repertoire of tumor antigens recognised by the immune system of cancer patients, referred to as the cancer immunome. In this regard, cancer/testis (CT) antigens are of particular interest because of their immunogenicity and restricted expression patterns. Synoivial sarcomas are striking with regard to CT antigen expression, however, highly expressed in sarcoma, CT antigens do not induce frequent humoral immune responses in sarcoma patients. Sera from two patients were used to immunoscreen cDNA libraries from two synovial sarcoma cell lines and normal testis, resulting in the identification of 113 distinct antigens. Sarcoma antigen NY-SAR-91 is one of them.
    Molecular Weight
    23 kDa (MW of target protein)
You are here:
Support